AACR annual meeting starts today -- virtually
Gilead's remdesivir may get swift Japanese approval for COVID-19
Axsome shares rocket on a surprise late-stage study win in Alzheimer's agitation
Compass raises $80M to take magic mushroom drug forward in treatment-resistant depression please scroll down for all the latest news*
